Oral Wegovy at $149/Month: Is the GLP-1 Pill Actually Worth It vs Compounded?
When oral Wegovy launched at $149/month for the starting dose, it reset the calculus for patients choosing between FDA-approved and compounded oral GLP-1s. The price gap has narrowed significantly — is the remaining premium worth paying?
The Price Gap in Numbers
| Oral Wegovy | Cheapest Compounded | Gap | |
|---|---|---|---|
| Starting dose | $149/mo | $99/mo (MadeMed) | $50/mo |
| Maintenance | $199–$299/mo | $147/mo (Wellorithm) | $52–$152/mo |
At the starting dose level, the gap is just $50/month — $600/year. That's the price of clinical trial validation, FDA-approved manufacturing, and proven SNAC absorption technology.
At maintenance doses, the gap widens. Oral Wegovy at $299/month versus Wellorithm at $147/month is a $152/month difference — $1,824/year. That's a more meaningful premium.
What You Get for the Premium
With oral Wegovy: a medication that's been through Phase 3 clinical trials, manufactured in FDA-inspected facilities, with validated absorption technology (SNAC), published efficacy data showing ~15% weight loss, and zero regulatory risk. No chance of your provider getting shut down by an FDA enforcement action.
With compounded: significant cost savings, more format variety (drops, tablets, gummies), and for most patients, effective weight loss — but with less clinical validation of the specific oral delivery method, some regulatory uncertainty, and reliance on the compounding pharmacy's formulation quality.
The Verdict
At the starting dose, oral Wegovy at $149 is arguably the best value in oral GLP-1s — $50/month more than the cheapest compounded option buys you FDA approval, clinical data, and regulatory certainty. At maintenance doses ($199–$299), the premium gets harder to justify for budget-conscious patients, and compounded alternatives offer legitimate savings.